Oncology

Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too

March 24, 2013

AudioMedica News

00:00 /

ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM study reported at the 2013 Genitourinary Cancers Symposium. Professor Cora Sternberg Chief of Medical Oncology at the San Camillo & Forlanini Hospitals in Rome gave Peter Goodwin more details about why this new generation hormonal therapy is appropriate and how effective it has proved to be in the AFFIRM study in general and among over 75s in particular.

LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/130310CoraSternbergAJOPODCASTLoRes.mp3]

Jenny Paredes PhD, Duarte, CA: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation

January 8, 2025

The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell...

AJO Audio Oncology

Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

December 17, 2024

Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia

AJO Audio News Oncology

Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

October 9, 2022

Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.

AJO Audio General Medicine Oncology

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer

October 4, 2022

Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant...

Infectious Disease AJO Cardiovascular General Medicine News Oncology Primary Health Care Public Health Video

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

May 28, 2020

Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...

Audio AJO Oncology

CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms

February 24, 2020

Audio Journal of Oncology Podcast CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms Play Episode Pause Episode 1x 00:00 / 20...

Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too

Further reading

Jenny Paredes PhD, Duarte, CA: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation

Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms

Menu

Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too

Further reading

Jenny Paredes PhD, Duarte, CA: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation

Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms

Menu

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer